Health · Medical Research · 3 hrs ago
US trial examines online disclosure of Alzheimer’s test results
Researchers tested online disclosure of Alzheimer’s-related results against sharing them with a clinician.
The remote US trial involved adults aged 60 to 80 who had previously taken an APOE genetic test but had not received their results.
Participants were assigned to an online platform or a genetic counsellor, and could ask for clinician help with the digital option.
APOE results can indicate genetic susceptibility to Alzheimer’s, while a blood test called p-tau217 can indicate disease-related changes.
The trial compared knowledge, anxiety and disease-related distress after people received their results.
This matters because patients may get test results online before speaking with a healthcare professional, and the findings could inform how sensitive information is shared.
Researchers also assessed blood-test disclosure, but the provided study details do not state the trial’s results or what happens next.
A US trial is examining whether older adults can receive Alzheimer’s-related test results safely through an online platform rather than from a clinician.
The eSMARTER trial compared digital disclosure of APOE genetic test results with disclosure by a genetic counselor through telehealth.
Researchers also compared outcomes after participants were offered blood tests for the Alzheimer’s-related biomarker p-tau217.
The study assessed participants’ knowledge, anxiety and disease-specific distress after results were disclosed.
- Who
- Researchers from Banner Alzheimer’s Institute, the University of Pennsylvania’s Perelman School of Medicine and Fox Chase Cancer Center conducted the study.
- What
- The eSMARTER trial compared digital and clinician-mediated disclosure of APOE results, and also assessed disclosure of p-tau217 results.
- When
- Recruitment ran from October 2024 to February 2025. Follow-up was completed in November 2025.
- Where
- The decentralized trial was conducted in the contiguous United States.
- Why
- Researchers examined whether digital disclosure could provide an alternative to clinician-led disclosure as genetic and blood-based Alzheimer’s testing expands.
This story does not have two clearly opposing sides.
Researchers recruited participants for the eSMARTER trial.
Participants were offered optional p-tau217 testing and disclosure through their assigned method.
Follow-up for the trial was completed.
- Trial name
- Evaluation of Self-Mediated Alternatives for Risk Testing Education and Return of Results (eSMARTER)
- Participants
- Adults aged 60 to 80 years
- Randomization
- Participants were assigned in a 2:1 ratio to digital or telehealth disclosure
- Digital options
- Secure web-based platform or SMS-based chat
- APOE follow-up
- Assessments at 1 to 7 days, 6 weeks and 6 months after disclosure
- p-tau217 follow-up
- Four weeks after disclosure